Skip to main content
. 2017 Oct;6(5):600–610. doi: 10.21037/tlcr.2017.07.02

Figure 4.

Figure 4

Suppression of NR4A2 and downstream targets by candidate agents. (A) EGFR and Src inhibitors as well as KU 171309 suppressed NR4A2 level; (B) inhibition of downstream pathways of EGFR and Src were assessed by western blotting. EGFR and Src inhibitors showed suppression of p-ERK, whereas KU171309 had no effect.